GlassScriptPhysician profile
Vasantha K Perkari
NPI 1215032156
$4,451.46
in general payments reported to CMS, 2019-2025
42 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $1,191 · 2021: $958 · 2022: $540 · 2023: $275 · 2024: $157 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $592.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $482.32 | 2020-2024 | |
| Pfizer INC. | $371.58 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $345.89 | 2020-2025 | Airsupra, Farxiga |
| Janssen Pharmaceuticals, INC | $340.39 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.05 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $170.48 | 2019-2021 | |
| Horizon Therapeutics Plc | $159.36 | 2019-2022 | |
| Lilly USA, LLC | $159.23 | 2020-2023 | Mounjaro |
| Sunovion Pharmaceuticals INC. | $158.07 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.43 | 2019-2020 | |
| Amgen INC. | $142.46 | 2019-2025 | Repatha, Otezla |
| Abbott Laboratories | $131.72 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Novartis Pharmaceuticals Corporation | $93.24 | 2019-2025 | |
| Glaxosmithkline, LLC. | $91.18 | 2019-2023 | Arexvy |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasantha Perkari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.